SEI Investments’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
RCM
SVCM
DM
SL
ACM
PCH
VCM
SEI Investments's MNPR Position: Q1 2026 in Review
SEI Investments increased its Monopar Therapeutics (MNPR) stake by 9.5% in Q1 2026, buying an estimated $39.6K and bringing the position to 7,582 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #2720.
SEI Investments first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $452K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.
- SEI Investments held 7,582 shares of Monopar Therapeutics worth $415K as of Q1 2026.
- SEI Investments bought 656 Monopar Therapeutics shares in Q1 2026, an estimated $39.6K.
- Monopar Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2720 holding.
- SEI Investments first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
- SEI Investments's Monopar Therapeutics position peaked at $452K in Q4 2025.
- 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.
Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.